Glenmark to Launch Generic Sodium Phosphates Injection in US Market in 2026

Glenmark Pharmaceuticals' US subsidiary plans to launch generic Sodium Phosphates Injection USP in April 2026, offering 15 mM P 5 mL, 45 mM P 15 mL, and 150 mM P 50 mL single-dose vials. The product is bioequivalent and therapeutically equivalent to Hospira Inc.'s reference drug, upon which the FDA based its safety and effectiveness approval. The market for these injections recorded approximately USD 66.8 million in sales for the year ending December 2025. Glenmark aims to provide affordable alternatives and expand its institutional product portfolio.